A/Prof Sumitra Ananda
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
134 Scholarly works
2 Projects
HIGHLIGHTS
2026
Journal article
Progress and challenges in expanding access to clinical trials in pancreatic cancer
DOI: 10.1038/s43856-026-01869-z2026
Journal article
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial
DOI: 10.1038/s41416-026-03535-62026
Journal article
Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.
DOI: 10.1016/S1470-2045(26)00223-82023
Research grants (other domestic)
REZOLV3R: Randomised Trial of Palliative Intraperitoneal Bevacizumab Following Therapeutic Drainage of Recurrent Malignant Ascites in Patients With Chemotherapy Resistant Solid Tumours
2021
Research Grant
HyNOVA - A Randomised Study Comparing Hyperthermic and Normothermic Intraperitoneal Chemotherapy Following Interval Cytoreductive Surgery for Stage III Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
2018
Journal article
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
DOI: 10.1038/s41467-018-05564-z2014
Journal article
Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts
DOI: 10.1016/j.molonc.2014.01.008
RECENT SCHOLARLY WORKS
2026
Journal article
Phase 1 faecal microbiota transplantation in patients with advanced pancreatic carcinoma (FMTPanc Trial).
DOI: 10.1200/jco.2026.44.16_suppl.tps42622026
Journal article
GOG-3119/ENGOT-en29/TroFuse-033: A phase 3, randomized study of sacituzumab tirumotecan plus pembrolizumab vs pembrolizumab alone as first-line maintenance therapy for mismatch repair-proficient endometrial cancer
DOI: 10.1016/j.ygyno.2026.01.1682026
Journal article
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
DOI: 10.1016/S0140-6736(26)00602-12026
Journal article
Abstract CT304: Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial) a Phase 1b 2a study-Interim analysis
DOI: 10.1158/1538-7445.am2026-ct3042026
Journal article
Azenosertib in combination with bevacizumab as maintenance therapy in patients with advanced ovarian cancer: part 2 of a phase 1b study
DOI: 10.1016/j.ijgc.2026.1046112026
Journal article
Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel as first-line treatment for patients with metastatic pancreatic cancer (ACCENT trial): Phase 2a results.
DOI: 10.1200/jco.2026.44.2_suppl.7352025
Journal article
SAFETY OF HYPERTHERMIC VERSUS NORMOTHERMIC INTRAPERITONEAL CHEMOTHERAPY FOLLOWING INTERVAL CYTOREDUCTIVE SURGERY FOR STAGE III EPITHELIAL OVARIAN CANCER
DOI: 10.1016/j.ijgc.2025.102164